Skip to content
← Full study record

NCT02375555 · MORE INFO

Limitations, agreements, and source contact

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM · Source last updated 2024-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Limitations include lack of comparator arm. Small sample size; unable to draw valid conclusions from comparison studies. Duration of follow-up was limited and longer-term assessment of patient safety is warranted. Tolerability data is limited as patient-reported outcomes data not collected.
point Of Contact
email
ajantha_nithi@dfci.harvard.edu
organization
Dana Farber Cancer Institute
phone
857-215-2829
title
Ajantha Nithi
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Limitations include lack of comparator arm. Small sample size; unable to draw valid conclusions from comparison studies. Duration of follow-up was limited and longer-term assessment of patient safety is warranted. Tolerability data is limited as patient-reported outcomes data not collected.
point Of Contact
email
ajantha_nithi@dfci.harvard.edu
organization
Dana Farber Cancer Institute
phone
857-215-2829
title
Ajantha Nithi

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice